Cellectis S.A. (CLLS): Price and Financial Metrics
CLLS Price/Volume Stats
| Current price | $1.46 | 52-week high | $4.04 |
| Prev. close | $1.54 | 52-week low | $1.37 |
| Day low | $1.37 | Volume | 231,987 |
| Day high | $1.55 | Avg. volume | 83,474 |
| 50-day MA | $1.83 | Dividend yield | N/A |
| 200-day MA | $2.11 | Market Cap | 81.15M |
CLLS Stock Price Chart Interactive Chart >
CLLS POWR Grades
- Value is the dimension where CLLS ranks best; there it ranks ahead of 75.55% of US stocks.
- The strongest trend for CLLS is in Stability, which has been heading up over the past 135 days.
- CLLS's current lowest rank is in the Momentum metric (where it is better than 14.08% of US stocks).
CLLS Stock Summary
- Of note is the ratio of CELLECTIS SA's sales and general administrative expense to its total operating expenses; merely 4.59% of US stocks have a lower such ratio.
- With a year-over-year growth in debt of -25.5%, CELLECTIS SA's debt growth rate surpasses just 12.95% of about US stocks.
- Revenue growth over the past 12 months for CELLECTIS SA comes in at -40.72%, a number that bests just 6.14% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to CELLECTIS SA are PNT, IMMP, RVMD, IONS, and CKPT.
- Visit CLLS's SEC page to see the company's official filings. To visit the company's web site, go to www.cellectis.com.
CLLS Valuation Summary
- In comparison to the median Healthcare stock, CLLS's price/sales ratio is 138.1% higher, now standing at 5.
- Over the past 102 months, CLLS's price/sales ratio has gone down 38.2.
Below are key valuation metrics over time for CLLS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CLLS | 2023-07-26 | 5.0 | 1.1 | -1.2 | -1.5 |
| CLLS | 2023-07-25 | 5.2 | 1.2 | -1.3 | -1.6 |
| CLLS | 2023-07-24 | 5.2 | 1.2 | -1.3 | -1.6 |
| CLLS | 2023-07-21 | 6.2 | 1.4 | -1.5 | -1.9 |
| CLLS | 2023-07-20 | 5.6 | 1.2 | -1.4 | -1.7 |
| CLLS | 2023-07-19 | 5.0 | 1.1 | -1.2 | -1.5 |
CLLS Growth Metrics
- The 2 year price growth rate now stands at -78.89%.
- The 3 year net cashflow from operations growth rate now stands at -42.08%.
- The 4 year net cashflow from operations growth rate now stands at -52.34%.
The table below shows CLLS's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 22.181 | -107.306 | -104.321 |
| 2022-06-30 | 31.087 | -111.689 | -113.267 |
| 2022-06-30 | 31.087 | -111.689 | -113.267 |
| 2022-03-31 | 42.937 | -100.245 | -134.239 |
| 2021-12-31 | 67.071 | -104.562 | -114.197 |
| 2021-09-30 | 69.317 | -117.368 | -128.669 |
Cellectis S.A. (CLLS) Company Bio
Cellectis SA is a preclinical stage biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. The company was founded in 1999 and is based in Paris, France.
Latest CLLS News From Around the Web
Below are the latest news stories about CELLECTIS SA that investors may wish to consider to help them evaluate CLLS as an investment opportunity.
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingNEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on MUC1-CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023), that will take place on November 1-5, 2023 at San |
Monthly information on share capital and company voting rights(Article 223-16 of General Regulation of the French financial markets authority)PARIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of votingrights08/31/202355,583,76861,519,936 About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherap |
Cellectis Provides Full Report for Second Quarter 2023 Financial ResultsNEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the release of the full report of the financial results for the second quarter 2023 (ended June 30, 2023) and filing of the corresponding 6-K with the SEC. Financial Results The interim condensed consolidated financial statements of Cellec |
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at the EHA annual meeting Clinical trials ongoing: BALLI-01 (evaluating UCART22), NATHALI-01 (evaluating UCART20x22) and AMELI-01 (evaluating UCART123) studies for patients with r/r B-cell ALL, r/r B-cell NHL and r/r AML, respectively Preclinical data presented on HBB gene correction of sickle cell mutation & TALE Base Editors (TALE-BE) at ISCT 2023 annual event Appointment of Cécile Chartier |
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter ended June 30, 2023 on Thursday, August 3, 2023 after the close of the US market. The announcement will be followed by an investor conference call and webcast on Friday, August 4 |
CLLS Price Returns
| 1-mo | N/A |
| 3-mo | -24.86% |
| 6-mo | N/A |
| 1-year | -39.42% |
| 3-year | -91.55% |
| 5-year | -94.85% |
| YTD | -30.48% |
| 2022 | -74.14% |
| 2021 | -69.99% |
| 2020 | 58.06% |
| 2019 | 2.82% |
| 2018 | -42.88% |
Continue Researching CLLS
Want to see what other sources are saying about Cellectis SA's financials and stock price? Try the links below:Cellectis SA (CLLS) Stock Price | Nasdaq
Cellectis SA (CLLS) Stock Quote, History and News - Yahoo Finance
Cellectis SA (CLLS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...